KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.45

Roussel M, Lauwers-Cances V, Macro M, et al. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood. 2022;139(18):2747-2757.

Blood 141(10) 1234

PMID36893003
PMCID-
DOI10.1182/blood.2023019751
发表日期2023-03-09
入排依据:Metadata indicates an oncology randomized phase 3 trial, but lacks abstract or keywords to confirm human subjects and specific survival/progression outcomes. Insufficient to establish eligibility without further review.
摘要

摘要

无摘要

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。